A North Texas company is getting acquired by a firm in Southern California.
Fulgent Genetics Inc. has entered into an agreement for Irving-based Inform Diagnostics, according to a recent announcement. The deal is for a total purchase price of approximately $170 million, subject to adjustments, paid from cash on hand.
The agreement will wrap up in the second quarter, subject to closing conditions, including regulatory approvals.
Fulgent, which is publicly traded, is a technology-based genetic testing company focused on patient care in oncology, infectious and rare diseases, and reproductive health.
Read the full story at Dallas Business Journal.
